shine-logo

SHINE Announces Chris Vessell as General Manager of Therapeutics Division

JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.

2022-05-23T14:37:54-05:00May 23, 2022|2022, News, News Releases, Therapeutics|

SHINE’s new name highlights technology competencies and multiple phase opportunities

A test engineer works in SHINE's manufacturing facility in Fitchburg, Wis. JANESVILLE, Wis., Sept. 21, 2021 – SHINE Medical Technologies LLC today announced that the company has [...]

2021-12-17T17:23:41-06:00September 22, 2021|2021, News, News Releases|

SHINE, EDH enter distribution agreement for SHINE’s non-carrier-added Lu-177

SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries

2021-12-17T17:36:27-06:00May 25, 2021|2021, Medical Isotopes, News, News Releases, Therapeutics|

SHINE, Phoenix merger focused on advancing fusion technology 

JANESVILLE and FITCHBURG, Wis., April 20, 2021 – SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE.

2021-12-17T17:37:03-06:00April 20, 2021|2021, News, News Releases, Nuclear Fusion|

SHINE announces weathertight production facility

SHINE Technologies announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building has been certified as weathertight, a major milestone with significance for SHINE.

2021-12-17T17:37:36-06:00March 25, 2021|2021, News, News Releases|

SHINE breaks ground on HQ and Therapeutics production facility

SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.

2021-12-17T17:38:43-06:00December 16, 2020|2020, News, News Releases, Therapeutics|

SHINE announces first sales of n.c.a. Lu-177

SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.

2021-12-17T17:38:58-06:00November 4, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|

SHINE closes $80-million

SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.

2021-12-16T20:07:17-06:00September 3, 2020|2020, News, News Releases|

SHINE & IOCB deliver Lu-177 doses to GE

SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).

2021-12-16T20:07:30-06:00January 21, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|
Go to Top